NewAmsterdam Pharma Company N.V. $NAMS Stock Position Trimmed by Medicxi Ventures Management Jersey Ltd

Medicxi Ventures Management Jersey Ltd cut its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 6.8% in the first quarter, Holdings Channel reports. The institutional investor owned 2,674,182 shares of the company’s stock after selling 195,383 shares during the period. NewAmsterdam Pharma makes up about 8.7% of Medicxi Ventures Management Jersey Ltd’s investment portfolio, making the stock its 2nd biggest holding. Medicxi Ventures Management Jersey Ltd’s holdings in NewAmsterdam Pharma were worth $85,601,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wells Fargo & Company MN boosted its stake in NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares during the period. Geode Capital Management LLC raised its stake in shares of NewAmsterdam Pharma by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock valued at $3,590,000 after acquiring an additional 437 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of NewAmsterdam Pharma by 5.3% in the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after acquiring an additional 544 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of NewAmsterdam Pharma by 26.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,510 shares of the company’s stock worth $193,000 after acquiring an additional 1,156 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Trading Up 4.8%

NAMS opened at $33.24 on Friday. NewAmsterdam Pharma Company N.V. has a 12-month low of $17.97 and a 12-month high of $42.21. The business’s fifty day simple moving average is $32.80 and its 200-day simple moving average is $33.14. The company has a market capitalization of $3.89 billion, a price-to-earnings ratio of -18.57 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The firm had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. On average, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the transaction, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $869,158.57. This trade represents a 72.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.74% of the stock is currently owned by insiders.

Analysts Set New Price Targets

NAMS has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Truist Financial initiated coverage on NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $48.60.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.